Research advances toward more effective, long-lasting and side effect-free cancer treatments
The Baylor team is building the case for SRC-3 as a promising therapeutic target for next-generation cancer immunotherapy.
Read More
The Baylor team is building the case for SRC-3 as a promising therapeutic target for next-generation cancer immunotherapy.
Read MoreThe findings in animal models warrant continuing investigations to develop a novel, more effective and longer-lasting cancer therapy.
Read More